Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The primary endpoint of this phase II trial is the objective response rate of the regimen.
The secondary endpoints include treatment-related toxicity, progression free survival and
overall survival and breast conserving rate.